SELECTIVE SPECTROPHOTOMETRIC DETERMINATION OF LEVODOPA

M. E. El-Kommos

Department of Pharmaceutical Chemistry, Faculty of Pharmacy Assiut University, Assiut, Egypt

ABSTRACT

A selective spectrophotometric method is developed for the quantitative determination of levodopa. The proposed method is based on the interaction of levodopa with thiosemicarbazide in an alkaline medium to form a red coloured product. At the maximum absorption of 500 nm, Beer's law is adhered to over the $0.5-8~\mu g/ml$ range. Mglar absorptivity of the coloured product is 2.58~x~10°. Job's plot indicates 1:2 ratio of levodopa to thiosemicarbazide. Results of analysis of Larodopa tablets by the proposed method agree well with those of U.S.P. xxi. The method is highly selective since a catecholic function with free adjacent positions is required.

INTRODUCTION

Levodopa, (-)-3-(3,4-dihydroxyphenyl)-L-alanine, is widely used in the treatment of arteriosclerotic, idiopathic and post-encephalitic parkinsonism and in the control of the neurological symptoms of chronic manganese poisoning.

Existing analytical methods for the determination of levodopa include non-aqueous titration 2,3, potentiometry 4, UV-spectrophotometry 3,5,6, colorimetry 7, fluorimetry 8, GLC and HPLC 10. The official B.P. 1980 and U.S.P. XXI procedures involve non-aqueous titrimetric and UV-spectrophotometric methods.

In the present paper, a simple, rapid and sensitive spectrophotometric assay of levodopa in pure and tablet forms is reported. The method is based on the interaction of levodopa with thiosemicarbazide to form a highly absorbing red coloured triazine derivative.

EXPERIMENTAL

Materials:

Levodopa, obtained as a gift from Roche Products Ltd-UK, was used as a working standard.

Thiosemicarbazide (BDH, UK), Hydrochloric acid AR (Prolabo, France).

Propan-2-01(Merck, F.R.Germany). Other solvents used were of analytical grade.

Larodopa tablete(each tablet contains 500 mg of levodopa) were obtained as a sample from Roche Products Ltd; - UK.

Reagents:

- 1- Thiosemicarbazide solution, 0.3 % w/v in distilled water. This solution is stable for 1 week at $\sim 4^{\circ}$ C.
- 2- Sodium hydroxide solution, 0.3 N.
- 3- Hydrochloric acid, 0.01 N.

Apparatus:

- 1- Uvidec-320 spectrophotometer, JASCO, Tokyo, Japan.
- 2- Z-230 centrifuge, Hermle Gmbh & Co., F.R. Germany.

Selective Spectrophotometric Determination of Levodopa

Preparation of Samples:

Powder: Accurately weigh about 25 mg of levodopa, dissolve in 20 ml of 0.01 N HCl in 50-ml volumetric flask and complete to volume with the same solvent. Dilute 5 ml of this solution to 50 ml in a volumetric flask with 0.01 N HCl.

Tablets: Weigh and finely powder 20 tablets. Accurately weigh a portion of the powder, equivalent to 25 mg of levodopa and extract with 0.01 N HCl by centrifungation for 5 min at a speed of 5,000 rpm (twice each with 5 ml). Dilute the mixed extracts with the same solvent to contain 50 mc of levodopa per ml.

Procedure:

Pipet 1.0 ml of the sample solution into a 10-ml volumetric flask. Add 1 ml of thiosemicarbazide solution and 1 ml of 0.3 N sodium hydroxide solution and mix thoroughly. Heat the mixture for 3 min in a water bath at 60±5°C, cool and dilute to volume with propan-2-°l. Measure the absorbance of the solution in 1 cm cell at 500 nm against a blank prepared under the same conditions using 1 ml of 0.01 N HCl instead of the sample solution. Calculate the concentration of levodopa from a calibration graph covering the range 5-80 mcg/ml (points taken in this investigation are: 5,10,20,30,40,50,60,70 and 80 mcg/ml) or from the following linear regression equation:

A = 0.1313 C - 0.0058

Where A = Recorded absorbabce

C = Concentration of levodopa in the final assay
solution in mc/ml

RESULTS AND DISCUSSION

Thiosemicarbazide has been used as a chromogenic reagent for the spectrophotometric determination of epinephrine 11, isoprenaline sulphate 12, methyldopa 13, dobutamine hydrochloride 14 and dopamine 15. This reagent reacts specifically with a catecholic function with free adjacent positions 16.

Reaction Involved:

The resulting coloured product has an absorption maximum of 500 nm and apparent molar absorptivity of 2.58×10^4 . Fig.1 shows the absorption spectra of levodopa, reagent and chromogen formed in both acidic and alkaline media. It seems apparent that changing pH of the medium to the alkaline side induces a type of tautomerism leading to a bathochromic shift of 95 nm.

The continuous molar variation of levodopa and thiosemicarbazide was performed using Job's plot. Standard solutions of levodopa (10⁻³ M) and aqueous solutions of thiosemicarbazide (10⁻³ M) were used. A series of mixtures of the two standard solutions in 11 different complementary proportions totalling 2 ml (from 0+2 to 2+0 inclusive, Fig. 2) were prepared, treated each with 1 ml of 0.3 N NaOH and subjected to the general assay procedure. Fig. 2 shows that the interaction between these two compounds occurs in the ratio 1:2.

Attempts to separate the chromogen in a pure form were unsuccessful owing to the formation of a resinous coloured mass. The possibility of formation of the thiosemicarbazone of the q-quinone, formed in situ, is unlikely as thiosemicarbazone formation is generally an acid catalysed reaction 17. In addition, no colour was produced when levodopa was allowed to react with semicarbazide under the same

conditions. Addition of thiosemicarbazide through the sulphur atom to the o-quinone (newly formed) in analogy to the addition of thiourea to catechol ^{18,19} is also unlikely, as levodopa was found to react with thiourea under the same conditions giving only a faint yellow colour. A nucleophilic attack of the o-quinone, formed in situ by the amino groups of the hydrazide moieties of 2 molecules of thiosemicarbazide, may occur ^{18,20} according to Scheme 1, in anology to the interaction of dopamine with thiosemicarbazide.

Optimization of Variables:

- a) Effect of thiosemicarbazide concentration. The optimum concentration of thiosemicarbazide leading to maximum colour intensity was found to be 0.03 % in the final solution, corresponding to 1 ml of 0.3 % thiosemicarbazide reagent per 10 ml of the reaction mixture.
- b) Effect of alkali concentration. The optimum concentration of sodium hydroxide leading to maximum intensity was found to be 0.03 N in the final solution, corresponding to 1 ml of 0.3 N NaOH per 10 ml of the reaction mixture. Alkali concentrations higher than 0.03 N may lead to partial decomposition of the coloured product.
- c) Effect of heating time. Maximum colour intensity was obtained after heating the original reaction mixture at $60\pm 5^{\circ}$ C for 3 min. After cooling to room temperature and dilution with propan-2-ol, the colour is stable for at least 3 hours.
- d) Effect of solvent. The solvent affects both the wavelength and intensity of maximum absorption. The solvents investigated were water, methanol, ethanol, propan-1-ol,

propan-2-01 and dimethylsulphoxide (DMSO). Fig. 3 shows that DMSO gives the highest absorption intensity and the longest λ_{max} . However, it was found that DMSO renders the colour unstable and, consequently, unsuitable for spectrophotometric measurements. Therefore, propan-2-ol was used as a diluting solvent in all experiments.

Quantification, Accuracy and Precision:

A linear correlation (r=0.9996) was found between absorbance at 500 nm and the concentration of levodopa in the range 0.5-8 mc² /ml in the final assay solution.

Statistical evaluation of the regression equation gives the following data:

> Standard deviation (S) = 0.0101 Variance ratio (F) = 9411.64Probability of correlation > 0.995

Beer's plot can be used also for calculation of concentration. The reproducibility of the procedure was determined by running 10 replicate samples, each containing 5 mc solutions levodopa per ml in the final assay solution. At this concentration level, the coefficient of variation was 0.84 %.

Application to Bulk Drug and Dosage Forms:

The suggested method was applied to the quantitative determination of levodopa in bulk and in Larodopa tablets in comparison with the U.S.P. XXI method (Table 1). The values of student's t and F ratio show no significant difference between the thiosemicarbazide and the pharmacopoeial methods.

Scheme 1.

Table 1: Assay of levodopa in bulk drug and dosage form by the thiosemicarbazide method.

Sample or tablets	Amount	Recovery %+SD.%*			
	taken, mg	Thiosemicarbazide method	Official method	t	F
Bulk drug	25	100.1+0.79	99.9+1.22	0.308	2.38
Bulk drug	50	99.7 <u>+</u> 0.86	99.8 <u>+</u> 1.17	0.154	1.85
Bulk drug	75	99.9 <u>+</u> 0.75	100.1+1.20	0.316	2.56
Larodopa tablets	100	98.5 <u>+</u> 0.82	98.8+0.92	0.544	1.26
Larodopa tablets	200	98.9 <u>+</u> 0.76	99.1 <u>+</u> 1.04	0.347	1.87


^{*} Mean of 5 determinations

a Tabulated t for 4 degrees of freedom at

P = 0.05 = 2.776

b Tabulated F for (4,4) degrees of freedom at

P 0.05=6.39







Fig. 2. Continuous molar variation plot.



<u>REFERENCES</u>

- 1) Martindale. The Extrapharmacopoeia, 28th Ed. by J.E. Reynolds and A.B. Prasad, The Pharmaceutical Press, London, p.886(1982).
- 2) British Pharmacopoeia 1980, H.M. Stationery Office, London, pp. 254, 535, 781 (1980).
- 3) United States Pharmacopoeia XXI th Revision, National Fomulary XVI, U.S. Pharmacopeial Convention, Rockville, pp. 585, 586 (1985)
- 4) E.M.Athanasiou-Malaki and M.A.Koupparis, Anal. Chim. Acta, 161, 349 (1984).
- 5) A.G. Davidson, J. Pharm. Biomed. Anal, 2, 45 (1984).
- 6) A.G. Davidson, J. Pharm. Sci., 73, 1582 (1984).
- 7) R.Gomez, R.B.Hagel and E.A.Mac Mullan, Analytical Profiles of Drug Substances, Vol. 5, Ed.K. Florey, Academic Press, N.Y., pp. 189(1976)
- 8) T.A. Shenaeva, V.Y. Kakush and I.V. Smirnov, Lab Delo, 692 (1984).
- 9) C.W. Gehrke and D.L. Stalling, Separ. Sci., 2,101 (1967)
- 10.) J.H. Knox and J.Jurand , J.Chromatogr., 125, 89 (1976).
- 11) R.B. Salama amd S.K. Khalil, J. Pharm. Sci., <u>63</u>,1301 (1974).
- 12) R.B. Salama and H.A. El-Obeid, Analyst, 101,136 (1976).
- 13) S.K. Khalil and R.B. Salama, J. Pharm. Pharmacol., 26, 972 (1974).
- 14) M.E.El-Kommos, Analyst, 108,380 (1983).
- 15) M.E.El-Kommos, J. Pharm. Belg., <u>42</u>, 371 (1987).
- 16) K.L.Bajaj, Ann. Chim. (Paris), 1,5 (1976).
- 17) J.Hine, "Physical Organic Chemistry", 2<u>nd</u> Ed.,McGraw Hill, New York, pp.254 (1962).
- 18) W.Foerst, Editor, "Newer Methods of Preparative Organic Chemistry", Vol. IV, Academic Press, London, pp. 139-154 (1968).
- 19.) J. Daneke, U. Jahnke, B. Pankow and H.W. Wanzlick, Tetrahedron Lett., 1271 (1970).
- 20) S. Patai, Editor, "The Chemistry of Quinonoid Compounds", Part 2, Wiley Interscience, N.Y., pp. 881-916 (1974).

طريقة طيفية انتقائية لتعيين ليفودوبا

ميشيل ايليا القماص ميشياء الصيدلة ـ جامعة أسيوط قسام الكيمياء الصيدلية ـ كلية الصيدلة ـ جامعة أسيوط

فى هذا البحث تم التوصل الى طريقة طيفية انتقائية للتعيين الكمى لمادة الليفودويا وهو دوا عيستخدم فى علاج مرض الباركنسون و وتعتماللوريقة على تفاعل الليفوديا مع ثيوسيميكارباذيدفى وسط قلوى لانتاع مركب أحمر اللون له ذروه أمتصاص عند ٥٠٠ ن م وتصل درجة الامتصاص الجزيئ للجوهر الملون الى ٢٥٨ره٠٠ و

ولقد تمت دراسة طيف الجوهر الملون الناتج فى الوسط الحامضي والوسيط القلوى وأيضا تم تقدير النسبة الجزيئية لليفودوي وثيوسيميا كاربازيد فى التفاعل حيث وجد أنها ١ : ٢ وبنا عليه تسم اقتسراح ميكانيكيسة التفاعل .

كما تمت دراسة كل العوامل التي تؤثر على التفاعل لمعرفة أحسن الظروف للتعيين الكمى من حيث الحساسية والسرعية ·

وقد استخدمت الطريقة فى تحليل ليفودوها فى صورته النقية وأيضافى صورة أقراص لارودوبا (شركة روش) ووجدت النتائج متطابقة مع نتائج طريقة دستور الادوية الامريكى ١٩٨٥٠